Equity
€737,077 ▲ 13.6%
N2DERM has made a profit in every financial year since 2009.
N2DERM
Lifetime
17 annual accounts with figures on one time axispeak €232,689 (2025)
€232,689▲ 15.7%
peak €145,569 (2025)
€145,569▲ 20.2%
peak €737,077 (2025)
€737,077▲ 13.6%
€209,924▲ 27.6%
peak 1.1 FTE (2023)
0.6 FTEunchanged
Board1 name since 2021
1 directorCASTELEIN Carine
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Gross margin from €201,034 to €232,689Dividend €57,081Equity from €648,589 to €737,077Debts from €164,525 to €209,924
Key points
from the 2025 annual accountsChecked score
96
Excellent
Financially stronger than 64% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,192 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025highest value
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 4.01, cash €400,814
Equity €737,077 (77.8% of total assets)
Figures for financial year 2025 (filed on 27-08-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 78% on liquidity, 41% on profitability and 57% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 34,693 companies had the same profile as N2DERM has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of N2DERM itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for N2DERM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €70,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 4.01 (4.41 in 2024), above the usual 1.5. Short-term debt is 22.2% and cash 42.3% of total assets. 22.2% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
27 days late
2024
26 days late
2023
21 days late
2022
23 days late
2021
29 days late
2020
31 days late
2019
40 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 28 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 26 August (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0899792190
Reappointment: CASTELEIN Carine (director)
General meeting of 14-12-2023 · Gazette deed
Registered office moved from Anderlecht to Wemmel
New registered office: Rue Frans Robbrechts 258, 1780 Wemmel · Previous registered office: Boulevard Prince de Liège 74, 1070 Anderlecht · Gazette deed
Incorporation
published on 25-08-2008 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| N2DERM Wemmel | €0.9m | €232,689 | 77.8% | 0.6 |
| CRANIOMAX Uccle | €1.0m | €262,718 | 51.9% | 0.8 |
| SOCIETE MEDICALE DRS VON FRENCKELL-GILLARD Fernelmont | €1.0m | €262,300 | 51.1% | 1 |
| Docteur Aurélie LEDOUX Ophtalmologie Namur | €0.9m | €267,796 | 80.3% | 1 |
| Dr. Vanhee Neurologie Kortrijk | €0.8m | €303,151 | 88.9% | 0.5 |
| GYNEMAJE Etterbeek | €0.9m | €254,377 | 78.0% | 1.3 |
| DR.LAUWERS Rinaldo Sint-Pieters-Leeuw | €1.5m | €253,220 | 64.7% | 0.5 |
These companies have the same main activity as N2DERM: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €832,000 and €1.5m, founded between 2009 and 2011.
Official details
Source: KBO- Status
- Active since 14-08-2008Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Joint committee
- 330Health institutions and services · annual accounts 2025
- Establishment unit
- 2.276.195.9611780 Wemmel, since 14-08-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 11-12-2025
Annual accounts 2025
- ≈ €430,000estimated
- €947,001▲ 16.5%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 27-08-2026
Insights on N2DERM
N2DERM files the abbreviated format. That format states no turnover. The gross margin rose from €83,446 in 2009 to €232,689 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about N2DERM
- What is the company number of N2DERM?
- The company number of N2DERM is 0899.792.190. The VAT number is the same number with BE in front: BE 0899.792.190.
- Where is N2DERM based?
- The registered office is at Fr. Robbrechtsstraat 258, 1780 Wemmel.Company details
- What does N2DERM do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of N2DERM?
- N2DERM is a private limited company (BV).
- When was N2DERM founded?
- N2DERM was founded on 14-08-2008.
- Is N2DERM still active?
- Yes, N2DERM is an active enterprise in the KBO register.
- How many employees does N2DERM have?
- N2DERM had an average of 0.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does N2DERM fall under?
- In its 2025 annual accounts, N2DERM states joint committee 330 (Health institutions and services).
- What is the turnover of N2DERM?
- The turnover in financial year 2025 is ≈ €430,000. This figure is estimated from the gross margin of €232,689 and 41 comparable companies (NACE 86220). It probably lies between €370,000 and €570,000.
- Is N2DERM profitable?
- In financial year 2025, N2DERM made a profit of €145,569.
- Where can I find the annual accounts of N2DERM?
- N2DERM filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of N2DERM due?
- N2DERM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.